FDA Accepts Roche’s Fenebrutinib NDA with Priority Review for Relapsing and Primary Progressive MS
Fenebrutinib priority review: the FDA accepted Roche’s NDA for the BTK inhibitor in relapsing and primary progressive MS, announced 30 September 2026.
Discover the latest updates and diverse insights across various topics at Med Pharma News. Stay informed with breaking news, in-depth analyses, and exclusive reports covering a wide spectrum of subjects relevant to the pharmaceutical and healthcare industries.
Fenebrutinib priority review: the FDA accepted Roche’s NDA for the BTK inhibitor in relapsing and primary progressive MS, announced 30 September 2026.